JP2013528650A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528650A5
JP2013528650A5 JP2013515459A JP2013515459A JP2013528650A5 JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5 JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5
Authority
JP
Japan
Prior art keywords
ylthio
bromo
triazol
acetic acid
cyclopropylnaphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528650A (ja
JP5964821B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040398 external-priority patent/WO2011159732A1/en
Publication of JP2013528650A publication Critical patent/JP2013528650A/ja
Publication of JP2013528650A5 publication Critical patent/JP2013528650A5/ja
Application granted granted Critical
Publication of JP5964821B2 publication Critical patent/JP5964821B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515459A 2010-06-15 2011-06-14 痛風と高尿酸血症の処置 Expired - Fee Related JP5964821B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US61/355,004 2010-06-15
US41144910P 2010-11-08 2010-11-08
US61/411,449 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US61/430,522 2011-01-06
US201161489420P 2011-05-24 2011-05-24
US61/489,420 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (3)

Publication Number Publication Date
JP2013528650A JP2013528650A (ja) 2013-07-11
JP2013528650A5 true JP2013528650A5 (enExample) 2014-06-05
JP5964821B2 JP5964821B2 (ja) 2016-08-03

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515459A Expired - Fee Related JP5964821B2 (ja) 2010-06-15 2011-06-14 痛風と高尿酸血症の処置

Country Status (19)

Country Link
US (3) US9216179B2 (enExample)
EP (1) EP2582683B1 (enExample)
JP (1) JP5964821B2 (enExample)
CA (1) CA2802407C (enExample)
CY (1) CY1120473T1 (enExample)
DK (1) DK2582683T3 (enExample)
ES (1) ES2670700T3 (enExample)
HR (1) HRP20180780T1 (enExample)
HU (1) HUE038265T2 (enExample)
LT (1) LT2582683T (enExample)
NO (1) NO2019008I1 (enExample)
PL (1) PL2582683T3 (enExample)
PT (1) PT2582683T (enExample)
RS (1) RS57275B1 (enExample)
SI (1) SI2582683T1 (enExample)
SM (1) SMT201800266T1 (enExample)
TR (1) TR201806828T4 (enExample)
WO (1) WO2011159732A1 (enExample)
ZA (1) ZA201300055B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
EP3501520A1 (en) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063788A1 (ja) 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
DK2135608T3 (da) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
CN101646440A (zh) 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2736117C (en) 2008-09-04 2013-11-19 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MX2012007925A (es) 2010-01-08 2012-08-03 Ardea Biosciences Inc Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas.
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
US20130296345A1 (en) * 2010-10-15 2013-11-07 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
LT2658846T (lt) 2010-12-30 2017-02-27 Ardea Biosciences, Inc. 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acto rūgšties polimorfinės formos ir jų panaudojimas
ES2633762T3 (es) 2011-05-24 2017-09-25 Ardea Biosciences, Inc. Hipertensión e hiperuricemia

Similar Documents

Publication Publication Date Title
JP2013528650A5 (enExample)
JP2013528655A5 (enExample)
JP5964821B2 (ja) 痛風と高尿酸血症の処置
Grassi et al. Clinical features of gout
JP2012184234A5 (enExample)
JP2014532726A5 (enExample)
JP6120985B2 (ja) ホスホジエステラーゼタイプ5活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
JP2009533356A5 (enExample)
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
JP2013087119A5 (enExample)
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
CN101500561A (zh) 应用铁螯合剂治疗内分泌功能障碍
JP2010509199A (ja) 過体重又は肥満の低減
US20150005506A1 (en) Therapeutic agent for diabetes
RU2014115733A (ru) Новая соль и медицинское применение
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP2018536638A5 (enExample)
EA028495B1 (ru) Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина
EP3834828B1 (en) Composition comprising a thiamine derivative for use in the prevention or treatment of vascular or cardiac valve calcification
CN118178378A (zh) 10-羟基-2-癸烯酸在防治高尿酸血症中的用途
EP4477223A4 (en) A pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt, combined for the prevention or treatment of chronic nephropathy in a patient with elevated blood uric acid levels.
CN110075100A (zh) 咖啡酸苯乙酯在制备治疗/预防高尿酸相关疾病的药物/保健品方面的应用
Wipfler-Freißmuth et al. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report
CN108420823A (zh) 一种选择性抑制痛风结石和尿酸肾结石晶体嘌呤衍生物的应用
JP6028983B2 (ja) ビダラビンによる心房細動治療